Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» February 2012
February 2012
Vivus rockets 99% on FDA nod
Vivus rockets 99% on FDA nod
Marketwatch
FDA
Vivus
obesity
Qnexa
Satori snags $15M to fuel a trial on Alzheimer's drug
Satori snags $15M to fuel a trial on Alzheimer's drug
Fierce Biotech
Satori
Alzheimer's disease
amyloid beta
Novartis Urged To Drop Gleevec Patent Case
Novartis Urged To Drop Gleevec Patent Case
Pharmalot
Gleevac
Novartis
patents
Par Pharma Absorbs Edict Pharma
Par Pharma Absorbs Edict Pharma
Yahoo/Zacks
Edict Pharmaceuticals
Par Pharmaceutical
Medicines Co 4Q profit slides, trumps expectations
Medicines Co 4Q profit slides, trumps expectations
Yahoo/AP
earnings
Medicines Company
Paladin and Somaxon Announce Filing of New Drug Submission for Silenor
Paladin and Somaxon Announce Filing of New Drug Submission for Silenor
Yahoo
Paladin
Somaxon
Silenor
Canada
insomnia
MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile
MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile
Yahoo
migraines
MAP Pharmaceuticals
patents
Johnson & Johnson CEO is Out, but not Gone
Johnson & Johnson CEO is Out, but not Gone
TheStreet.com
William Weldon
Pharma CEOs
JNJ
Ranbaxy Reports $606 Million Loss After U.S. Settlement
Ranbaxy Reports $606 Million Loss After U.S. Settlement
Bloomberg
Ranbaxy
earnings
FDA panel overwhelmingly backs previously rejected anti-obesity pill Qnexa
FDA panel overwhelmingly backs previously rejected anti-obesity pill Qnexa
Washington Post, DC
FDA
Vivus
obesity
Qnexa
advisory panel
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
…
next ›
last »